Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 4573

1.

Management of bleeding with oral anticoagulants in patients with atrial fibrillation.

Bosch J, Eikelboom JW.

Hamostaseologie. 2015 May 27;35(3). [Epub ahead of print]

PMID:
26013362
2.

Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital.

Tellor KB, Patel S, Armbruster AL, Daly MW.

J Clin Pharm Ther. 2015 May 26. doi: 10.1111/jcpt.12288. [Epub ahead of print]

PMID:
26010016
3.

Rationale and design of the RT-AF study: Combination of Rivaroxaban and Ticagrelor in Patients with Atrial Fibrillation and Coronary Artery Disease undergoing Percutaneous Coronary Intervention.

Gao F, Shen H, Wang ZJ, Yang SW, Liu XL, Zhou YJ.

Contemp Clin Trials. 2015 May 20. pii: S1551-7144(15)30011-2. doi: 10.1016/j.cct.2015.05.012. [Epub ahead of print]

PMID:
26003433
4.
5.

Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role.

Longhi S, Quarta CC, Milandri A, Lorenzini M, Gagliardi C, Manuzzi L, Bacchi-Reggiani ML, Leone O, Ferlini A, Russo A, Gallelli I, Rapezzi C.

Amyloid. 2015 May 21:1-9. [Epub ahead of print]

PMID:
25997105
6.

Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients with atrial fibrillation: a nationwide cohort study.

Staerk L, Gislason GH, Lip GY, Fosbøl EL, Hansen ML, Lamberts M, Bonde AN, Torp-Pedersen C, Olesen JB.

Europace. 2015 May 19. pii: euv119. [Epub ahead of print]

PMID:
25995392
7.

Stroke prevention in atrial fibrillation: a systematic review.

Lip GY, Lane DA.

JAMA. 2015 May 19;313(19):1950-62. doi: 10.1001/jama.2015.4369. Review.

PMID:
25988464
8.

Feasibility and safety of uninterrupted dabigatran therapy in patients undergoing ablation for atrial fibrillation.

Nagao T, Inden Y, Shimano M, Fujita M, Yanagisawa S, Kato H, Ishikawa S, Miyoshi A, Okumura S, Ohguchi S, Yamamoto T, Yoshida N, Hirai M, Murohara T.

Intern Med. 2015;54(10):1167-73. doi: 10.2169/internalmedicine.54.3520. Epub 2015 May 15.

9.

Amiodarone use is associated with increased risk of stroke in patients with nonvalvular atrial fibrillation: a nationwide population-based cohort study.

Chen WC, Chen WC, Chen CY, Wu BR, Cheng WC, Lin KH, Hsia TC, Chen W, Chen CH, Muo CH, Liao WC, Li CH.

Medicine (Baltimore). 2015 May;94(19):1-6. doi: 10.1097/MD.0000000000000849.

PMID:
25984674
10.

The impact of inpatient rivaroxaban versus warfarin on hospital-based outcomes when used for stroke prevention in patients with anticoagulant naïve, new-onset nonvalvular atrial fibrillation.

Hurley C, Dai S, Sobieraj DM.

Int J Cardiol. 2015 May 1;192:1-2. doi: 10.1016/j.ijcard.2015.04.240. [Epub ahead of print] No abstract available.

PMID:
25981569
11.

Antiphospholipid Syndrome of Late Onset: A Difficult Diagnosis of a Recurrent Embolic Stroke.

Delgado MG, Rodríguez S, García R, Sánchez P, Sáiz A, Calleja S.

J Stroke Cerebrovasc Dis. 2015 May 12. pii: S1052-3057(15)00209-8. doi: 10.1016/j.jstrokecerebrovasdis.2015.04.016. [Epub ahead of print]

PMID:
25979425
12.

Antithrombotic treatment for stroke prevention in atrial fibrillation: The Asian agenda.

Chen CH, Chen MC, Gibbs H, Kwon SU, Lo S, On YK, Rosman A, Suwanwela NC, Tan RS, Tirador LS, Zirlik A.

Int J Cardiol. 2015 Mar 27;191:244-253. doi: 10.1016/j.ijcard.2015.03.369. [Epub ahead of print] Review.

PMID:
25978611
13.

What neurosurgeons need to know about dabigatran etexilate (pradax(®)/pradaxa(®)/prazaxa(®)).

Dwyer CM, Damodaran O, Heckelmann M, Sheridan MM.

Asian J Neurosurg. 2015 Apr-Jun;10(2):66-8. doi: 10.4103/1793-5482.144156.

14.

Validation of Risk Scoring System Excluding Female Sex From CHA<sub>2</sub>DS<sub>2</sub>-VASc in Japanese Patients With Nonvalvular Atrial Fibrillation - Subanalysis of the J-RHYTHM Registry.

Tomita H, Okumura K, Inoue H, Atarashi H, Yamashita T, Origasa H, Tsushima E; J-RHYTHM Registry Investigators.

Circ J. 2015 May 13. [Epub ahead of print]

15.

Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial.

Steffel J, Giugliano RP, Braunwald E, Murphy SA, Atar D, Heidbuchel H, Camm AJ, Antman EM, Ruff CT.

Eur Heart J. 2015 May 13. pii: ehv201. [Epub ahead of print]

PMID:
25971288
16.

A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.

Lip GY, Merino J, Ezekowitz M, Ellenbogen K, Zamoryakhin D, Lanz H, Jin J, Al-Saadi N, Mercuri M, Goette A.

Am Heart J. 2015 May;169(5):597-604.e5. doi: 10.1016/j.ahj.2015.02.009. Epub 2015 Feb 21.

PMID:
25965706
17.
18.

The Long-Term Use of Warfarin Among Atrial Fibrillation Patients Discharged From an Emergency Department With a Warfarin Prescription.

Atzema CL, Austin PC, Chong AS, Dorian P, Jackevicius CA.

Ann Emerg Med. 2015 May 8. pii: S0196-0644(15)00231-0. doi: 10.1016/j.annemergmed.2015.03.024. [Epub ahead of print]

PMID:
25964082
19.

A Comparison of Dabigatran With Warfarin for Stroke Prevention in Atrial Fibrillation in an Asian Population.

Yap LB, Eng DT, Sivalingam L, Rusani BI, Umadevan D, Muhammad Z, Koh KW, Aisha B, Hashim MI, Rebo R, Hussin A, Kaur S, Shanmugam R, Omar R.

Clin Appl Thromb Hemost. 2015 May 11. pii: 1076029615584664. [Epub ahead of print]

PMID:
25962393
20.

Balancing the Risk of Bleeding and Stroke in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry).

Mennuni MG, Halperin JL, Bansilal S, Schoos MM, Theodoropoulos KN, Meelu OA, Sartori S, Giacoppo D, Bernelli C, Moreno PR, Krishnan P, Baber U, Lucarelli C, Dangas GD, Sharma SK, Kini AS, Tamburino C, Chieffo A, Colombo A, Presbitero P, Mehran R.

Am J Cardiol. 2015 Apr 8. pii: S0002-9149(15)01039-5. doi: 10.1016/j.amjcard.2015.03.033. [Epub ahead of print]

PMID:
25956624
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk